Education
About Us
Working with TipRanks
Follow Us
Response Genetics (RGDXQ)
:RGDXQ
RGDXQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume30.00K
Average Volume (3M)0.00
Market Cap
$39.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding38,795,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
15.47% Other Institutional Investors
84.53% Public Companies and
Individual Investors
RGDXQ FAQ
What was Response Genetics’s price range in the past 12 months?
Response Genetics lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Response Genetics’s market cap?
Response Genetics’s market cap is $39.00.
When is Response Genetics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Response Genetics’s earnings last quarter?
Currently, no data Available
Is Response Genetics overvalued?
According to Wall Street analysts Response Genetics’s price is currently Overvalued.
Does Response Genetics pay dividends?
Response Genetics does not currently pay dividends.
What is Response Genetics’s EPS estimate?
Response Genetics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Response Genetics have?
Response Genetics has 38,795,000 shares outstanding.
What happened to Response Genetics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Response Genetics?
Currently, no hedge funds are holding shares in RGDXQ
Company Description
Response Genetics
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Technical Analysis
Precipio
―
BioNano Genomics
―
Intelligent Bio Solutions
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―